3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
3
Withdrawn
1
Unknown
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
42
Lung Neoplasms
13
Neoplasms
7
Brain Neoplasms
6
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
NSCLC
3
Gastrointestinal Neoplasms
2
Esophageal Neoplasms
2
Central Nervous System Neoplasms
2
Breast Neoplasms
2
Adenocarcinoma, Bronchiolo-Alveolar
2
Adenocarcinoma of Lung
2
Tongue Neoplasms
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Respiratory Tract Diseases
1
Relapsed Pediatric Solid Tumor
1
Recurrence
1
Precancerous Conditions
1
Optic Nerve Glioma
1
Non-squamous Non-small Cell Lung Cancer
1
Metastatic Pancreatic Adenocarcinoma
1
Medulloblastoma
1
Lung Diseases
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Familial ependymoma
1
Interventions
Radiotherapy
4
Magnetic Resonance Spectroscopy
2
Fluorodeoxyglucose F18
2
Docetaxel
2
Cisplatin
2
fluoromisonidazole
1
aldesleukin
1
X-Rays
1
Rubidium-82
1
Ritonavir
1
Psychiatric Rehabilitation
1
Observation
1
Neoadjuvant Therapy
1
Neck Dissection
1
Luteolin
1
Indinavir
1
Glossectomy
1
Fluorouracil
1
Erlotinib Hydrochloride
1
DMAC2L protein, human
1
Chemotherapy, Adjuvant
1
Celecoxib
1
Anesthesia, Intravenous
1
5-fluoropentyl-2-methylmalonic acid
1
26S proteasome non-ATPase regulatory subunit 13
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Tongue Neoplasms
×
Erlotinib Hydrochloride
×
Clear all
NCT02748707
2022-04-28
ERLO-XIB
Tata Memorial Hospital
Phase 2
Unknown
64 enrolled